Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs
Eli Lilly (LLY) reported strong third-quarter results, driven significantly by its GLP-1 portfolio. Zepbound and Mounjaro accounted for 66% of the company's $24.4 billion total revenue, with Zepbound growing 49% year-over-year and Mounjaro increasing 65%. Despite this dominance in the obesity and diabetes sectors, the company is successfully diversifying its revenue streams through other therapeutic areas. Key growth drivers outside of weight loss include Kisunla for Alzheimer's disease, Jaypirca for cancer, and immunology therapies Ebglyss and Omvoh. These products have shown significant year-over-year revenue increases, ranging from 59% to 175%. Recent label expansions for these drugs are expected to expand their addressable markets and contribute meaningfully to medium-term sales growth.
Tickers: $LLY
Topics: diabetes treatment pharmaceuticals quarterly earnings weight loss drugs
Read the full article at Motley Fool
Part of the story Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs (10 articles)